Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-610 in severe eosinophilic asthma
NCT05528679Phase 2Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 610 in eosinophilic asthma (EA) (3 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoint: Change from baseline in pre-bronchodilator forced expiratory volume in one second (FEV1) at 16 weeks. Status: unknown.
02
Drugs
610
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT05528679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528679.